Gilead starts Phase II NX 211 cancer study

GILD began U.S. open-label Phase II testing in up to 58 patients of its NX 211 liposomal formulation of lurtotecan topoisomerase I inhibitor to treat ovarian cancer that has relapsed or progressed wit...